An ongoing phase II trial of infigratinib—an oral FGFR inhibitor for advanced CCA with FGFR abnormalities (gene fusion, translocation or other genetic alterations)—showed interesting results, with an overall response rate of 14.8% (FGFR2 fusion present only at a response rate of 18.8%).73 Here, FGFR2 is linked to cholangiocarcinoma.